MSI1 already represents a potential therapeutic target for the treatment of glioblastoma, as luteolin has been shown to inhibit the RNA-binding properties of MSI1 and disrupts cancer phenotypes in glioblastomas [77]. Here, MSI1 is linked to glioblastoma.